Erin Johanek, PharmD

The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year. 

DMARDs and the JAK Inhibitors have improved RA treatment. But not many new drugs are in the offing at the moment.

The first FDA-approved product for NASH on the horizon.

Find out what’s in the drug pipeline for autoimmune disease.

A large-scale observational study led by Columbia University researchers may offer new approach to studying diverse patient groups.